The vaccine group says there is no long-term need for second-line supplements for the elderly

A group of vaccine consultants in the UK on Friday said there was “no urgent need” for a second shot for at-risk elderly people, citing new evidence that vaccine protection against the deadly Omicron coronavirus was maintained for three months.

Information from the UK Health Security Agency, released Friday. cent.

“Current data suggest that increased levels continue to provide adequate protection against chronic diseases, even for high-risk older adults,” said Prof Wei Shen Lim, chair of the Covid-19 on the Joint Committee on Vaccination and Immunization. “For this reason the committee has found that there is no need to comment on the second level of supplementation, although this should continue to be reviewed.”

This week, Israel stayed the first country to offer the fourth level The BioNTech / Pfizer vaccine for the general public, is over 60 years old, medical staff and people with weakened immune systems amid a large number of cases due to Omicron.

A study of 150 Israeli health workers found five jumps in antibody groups after a fourth jab.

An estimated 500,000 insecure people in the UK have been eligible for the fourth dose within three months from the end of November.

The European Medicines Agency signed a declaration last year to assess whether a fourth dose is required for a wide range of people at risk, such as those who are not immune.

The UK has an additional 150m vaccine importers from Pfizer and Moderna, the current linchpins for its release, which are expected to arrive by 2022 and 2023.

Average over 35m third has been in the UK since the launch of the campaign in September but, despite the vaccine’s high immunization, Omicron pushed the risk of disease to record, and one in 15 people in England contracted Covid-19 last week December 31, according to at the National Statistics office.

This week, Prof Andrew Pollard, director of the Oxford Vaccine Group who created the Oxford / AstraZeneca jab, questioned the need for reassurance over time.

“It is not cheap, stable or requires any vaccine in the world for four or six months,” Pollard told the BBC. Today software.

“We have not been able to eradicate any vaccine in Africa by one level so we do not reach the fourth level of every single human being.”

“We may need to have incentives for vulnerable people, but I think it is unlikely that we will have programs for more than 12 years,” he added.